Early-stage HIV vaccine triggers targeted immune response in human trial

Worldwide, an estimated 40 million people live with HIV. Two-thirds of this group are on the African continent. In 2023, more than 600,000 people died from HIV-related causes and 1.32 million were infected. There is no vaccine against the world's second most deadly infection, after TB. However, researchers from Amsterdam UMC have set an important first step in reaching that goal. The results of their phase one trial are published in Science.

👉 Full Story